tiprankstipranks

Portage Biotech Granted Nasdaq Compliance Extension

Story Highlights
  • Portage Biotech received a compliance extension from Nasdaq for listing requirements.
  • The extension is crucial for Portage to maintain its market position and stakeholder confidence.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Portage Biotech Granted Nasdaq Compliance Extension

Portage Biotech Inc ( (PRTG) ) has provided an announcement.

On February 12, 2025, Portage Biotech Inc. announced that it received an extension from Nasdaq to comply with the stock exchange’s minimum shareholders’ equity requirement. This extension allows the company to continue its listing on the Nasdaq Capital Market while they work towards meeting these standards. Failure to comply by June 9, 2025, or not showing consistent progress could lead to delisting proceedings. This development is crucial for Portage Biotech as it strives to maintain its market position and provide confidence to its stakeholders.

More about Portage Biotech Inc

Portage Biotech Inc. is a clinical-stage immuno-oncology company that is developing a portfolio of innovative therapeutics aimed at enhancing the immune system’s ability to combat cancer.

YTD Price Performance: 3.28%

Average Trading Volume: 705,442

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $5.34M

See more data about PRTG stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App